In a report released today, Matthew Keller from H.C. Wainwright reiterated a Buy rating on Galectin Therapeutics, with a price target of $6.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Matthew Keller has given his Buy rating due to a combination of factors that highlight Galectin Therapeutics’ potential for growth. The company’s lead asset, belapectin, is showing promise in treating MASH-associated liver cirrhosis and portal hypertension, particularly in patients without baseline varices. Despite not achieving the primary endpoint in earlier trials, belapectin demonstrated a significant positive effect in a specific subgroup, indicating its potential as an earlier stage therapy.
Furthermore, the NAVIGATE trial, which assessed belapectin over 36 months, showed a reduction in the incidence of varices in the treatment group, although it did not reach statistical significance in the primary analysis. However, in a pre-specified per-protocol population, belapectin significantly reduced varices incidence, supporting its continued investigation. The company’s strategic focus on regulatory engagement and potential partnerships, along with its financial runway through 2Q26, further supports Keller’s optimistic outlook on Galectin Therapeutics.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GALT in relation to earlier this year.